Similarly, the inhibition of KCa3.1, a calcium-activated potassium channel, has been associated with PI3K/AKT activation, GSK3β suppression, and NF-κB inhibition, leading to neuroprotection and cognitive improvements in AD models. Here, GSK3B is linked to Alzheimer disease.